Magnetic Nanoparticles as MRI Contrast Agents

Iron oxide nanoparticles (IONPs) have emerged as a promising alternative to conventional contrast agents (CAs) for magnetic resonance imaging (MRI). They have been extensively investigated as CAs due to their high biocompatibility and excellent magnetic properties. Furthermore, the ease of functiona...

Descripción completa

Detalles Bibliográficos
Autores: Avasthi, Ashish, Caro, Carlos, Pozo-Torres, Esther, Pernia Leal, Manuel, García-Martín, María Luisa
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18045
Acceso en línea:http://hdl.handle.net/20.500.12105/18045
Access Level:acceso abierto
Palabra clave:Magnetic nanoparticles
Iron oxide nanoparticles
Magnetic resonance imaging
Cancer
Diagnosis
Nanopartículas magnéticas de óxido de hierro
Imagen por resonancia magnética
Neoplasias
Diagnóstico
Animals
Contrast Media
Humans
Magnetic Resonance Imaging
Magnetite Nanoparticles
Neoplasms
Descripción
Sumario:Iron oxide nanoparticles (IONPs) have emerged as a promising alternative to conventional contrast agents (CAs) for magnetic resonance imaging (MRI). They have been extensively investigated as CAs due to their high biocompatibility and excellent magnetic properties. Furthermore, the ease of functionalization of their surfaces with different types of ligands (antibodies, peptides, sugars, etc.) opens up the possibility of carrying out molecular MRI. Thus, IONPs functionalized with epithelial growth factor receptor antibodies, short peptides, like RGD, or aptamers, among others, have been proposed for the diagnosis of various types of cancer, including breast, stomach, colon, kidney, liver or brain cancer. In addition to cancer diagnosis, different types of IONPs have been developed for other applications, such as the detection of brain inflammation or the early diagnosis of thrombosis. This review addresses key aspects in the development of IONPs for MRI applications, namely, synthesis of the inorganic core, functionalization processes to make IONPs biocompatible and also to target them to specific tissues or cells, and finally in vivo studies in animal models, with special emphasis on tumor models.